Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well glembatumumab vedotin works in treating patients with
osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory).
Monoclonal antibodies, such as glembatumumab vedotin, may find tumor cells and help kill
them.